Business
Vistagen to Present at The Menopause Society 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif., October 16, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting in Orlando, Florida, on Thursday, October 23, 2025.
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/213c1a46d8f5ed4c519c0e8c817920c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MEUifh_06GS214ayNp.i9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/213c1a46d8f5ed4c519c0e8c817920c5","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pkices5IY7lSvZcqsWxUPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/213c1a46d8f5ed4c519c0e8c817920c5","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Posters Highlight New Insights into PH80’s Effects on Brain and Autonomic Activity","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., October 16, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting in Orlando, Florida, on Thursday, October 23, 2025.","length":469,"tagName":"p"},{"type":"text","content":"PH80 is Vistagen’s novel, non-systemic, non-hormonal, rapidly acting clinical stage pherine product candidate being evaluated as a potential treatment of vasomotor symptoms (hot flashes) due to menopause. The Company’s posters will discuss data from nonclinical and Phase 1 clinical studies of PH80.","length":299,"tagName":"p"},{"type":"text","content":"Poster Presentations:Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern TimeTitle: PH80 Nasal Spray: In Vitro Receptor Binding, Effects on Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans— A Potential, Novel, Rapid, Non-hormonal Treatment for Vasomotor Symptoms due to MenopauseAuthors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhDPoster Number: P-124","length":402,"tagName":"p"},{"type":"text","content":"Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern TimeTitle: PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Potent...